These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29605513)

  • 21. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry Survey.
    Beninger P; Caubel P; Sharma L; Pajovich G; Boyd P
    Clin Ther; 2022 Sep; 44(9):1225-1236. PubMed ID: 35940940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificial Intelligence in Pharmacovigilance: Scoping Points to Consider.
    Hauben M; Hartford CG
    Clin Ther; 2021 Feb; 43(2):372-379. PubMed ID: 33478803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacovigilance and the digital world in Italy: presentation of the results of a national survey.
    Stagi L; Bocchi I; Bianco S; Sirizzotti G; Bernardini D; Calderazzo V; Pirisino G; Grisoni I; Romano S
    Ther Adv Drug Saf; 2021; 12():2042098620985991. PubMed ID: 33623659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artificial Intelligence, Real-World Automation and the Safety of Medicines.
    Bate A; Hobbiger SF
    Drug Saf; 2021 Feb; 44(2):125-132. PubMed ID: 33026641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
    Edwards B
    Drug Saf; 2004; 27(8):609-17. PubMed ID: 15154832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Statistical Modeling for Enhanced and Flexible Pharmacovigilance Audit Risk Assessment and Planning.
    Zou M; Barmaz Y; Preovolos M; Popko L; Ménard T
    Ther Innov Regul Sci; 2021 Jan; 55(1):190-196. PubMed ID: 32804381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe.
    Portnoff JM; Lewis DJ
    Ther Innov Regul Sci; 2017 Jul; 51(4):486-493. PubMed ID: 30227052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacovigilance in Russia: current state of affairs, challenges, and prospects.
    Gildeeva G; Belostotsky A
    Curr Med Res Opin; 2017 Dec; 33(12):2161-2166. PubMed ID: 28562116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancing Drug Safety Through Prospective Pharmacovigilance.
    Pitts PJ; Le Louet H
    Ther Innov Regul Sci; 2018 Jul; 52(4):400-402. PubMed ID: 29714580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey.
    Tang Y; Liu Y; Liao H; Yuan Y; Jiang Q
    BMC Health Serv Res; 2023 Feb; 23(1):152. PubMed ID: 36788574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety.
    Olsen AK; Whalen MD
    Drug Saf; 2009; 32(10):805-10. PubMed ID: 19722724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries.
    Kovacs SD; Mills BM; Stergachis A
    Malar J; 2017 Jul; 16(1):282. PubMed ID: 28693488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
    Ghosh R; Lewis D
    Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacovigilance in oncology: evaluation of current practice and future perspectives.
    Baldo P; De Paoli P
    J Eval Clin Pract; 2014 Oct; 20(5):559-69. PubMed ID: 24909067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
    van Eekeren R; Rolfes L; Koster AS; Magro L; Parthasarathi G; Al Ramimmy H; Schutte T; Tanaka D; van Puijenbroek E; Härmark L
    Drug Saf; 2018 Nov; 41(11):1003-1011. PubMed ID: 29949100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.